Traws Pharma Reports Q2 2025 Financial Results

An update from Traws Pharma ( (TRAW) ) is now available.

On August 14, 2025, Traws Pharma announced its financial results for the second quarter of 2025 and highlighted progress in its antiviral programs. The company is advancing ratutrelvir, a ritonavir-free protease inhibitor for COVID-19, with Phase 2 studies planned to assess its efficacy and safety in newly diagnosed patients and those ineligible for PAXLOVID®. Additionally, Traws is working on Tivoxavir Marboxil (TXM) for influenza, emphasizing stockpiling readiness. These developments aim to position Traws as a leader in antiviral treatments, addressing the shortcomings of current therapies and potentially setting new standards of care.

The most recent analyst rating on (TRAW) stock is a Buy with a $7.00 price target. To see the full list of analyst forecasts on Traws Pharma stock, see the TRAW Stock Forecast page.

Spark’s Take on TRAW Stock

According to Spark, TipRanks’ AI Analyst, TRAW is a Underperform.

Traws Pharma’s overall stock score is low due to significant financial challenges and bearish technical indicators. However, recent corporate events, including positive trial data and new financing, provide a glimmer of hope for future improvements, albeit with high risk.

To see Spark’s full report on TRAW stock, click here.

More about Traws Pharma

Traws Pharma, Inc. is a clinical-stage biopharmaceutical company focused on developing novel therapies targeting critical threats to human health from respiratory viral diseases. The company’s primary products include antiviral candidates for COVID-19 and influenza, with a market focus on addressing unmet medical needs and potential stockpiling opportunities.

Average Trading Volume: 1,179,980

Technical Sentiment Signal: Sell

Current Market Cap: $9.07M

For a thorough assessment of TRAW stock, go to TipRanks’ Stock Analysis page.